This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clorox (CLX) Q3 Earnings Beats Estimates, Trims '18 EPS View
by Zacks Equity Research
Clorox (CLX) delivered solid third-quarter fiscal 2018 results driven by its 2020 Strategy and other initiatives. However, management cut down its earnings guidance for the fiscal year.
Clorox (CLX) Beats on Q3 Earnings & Sales, Revises FY18 View
by Zacks Equity Research
Clorox (CLX) reported third-quarter fiscal 2018 results, wherein earnings from continuing operations of $1.37 per share beat the Zacks Consensus Estimate of $1.30.
Clorox Expands Dietary Supplements Business, Buys Nutranext
by Zacks Equity Research
Clorox (CLX) expands its dietary supplements business by acquiring Nutranext for $700 million.
Why Is Clorox (CLX) Down 6.7% Since its Last Earnings Report?
by Zacks Equity Research
Clorox (CLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clorox (CLX) Q2 Earnings Top Estimates, Sales Miss
by Zacks Equity Research
Clorox Company (CLX) reported second-quarter fiscal 2018 earnings of $1.77 per share beating the Zacks Consensus Estimate of $1.22.
EL Vs CLX: Which Stock is Poised for Better Q2 Earnings?
by Zacks Equity Research
The fourth-quarter earnings season has turned out to be pretty well so far. Estee Lauder and Clorox are likely to report their quarterly results tomorrow.
The Zacks Analyst Blog Highlights: Comcast, United Technologies, Intel, Total System Services and Clorox
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, United Technologies, Intel, Total System Services and Clorox
Archer Daniels' (ADM) New Innovation Center to Woo Customers
by Zacks Equity Research
Archer Daniels (ADM) opens a new innovation center in Singapore in order to be more accessible to its customers. This is likely to strengthen its footprint in Southeast Asia.
Forget Archer Daniels, Buy These 3 Consumer Staples Stocks
by Zacks Equity Research
The Consumer Staples sector has been gaining from a buoyant U.S. economy. While Archer Daniels is battling several challenges, there are stocks gaining from the current economic trends.
4 Factors That Make Church & Dwight (CHD) a Lucrative Bet Now
by Zacks Equity Research
Church & Dwight (CHD) stock has been moving up the charts, thanks to its focus on innovations which have also helped the company to put up an impressive past record.
Clorox Hits 52-Week High: Will the Uptrend Continue in 2018?
by Zacks Equity Research
Clorox (CLX) has emerged as a sound investment opportunity supported by robust strategic initiatives, brand strength and 2020 Strategy.
Clorox (CLX) Strengthens Home Care Unit, Expands in Atlanta
by Zacks Equity Research
Clorox (CLX) announced the opening of a manufacturing facility in Atlanta, which is likely to strengthen the Home Care business.
Clorox (CLX) Tops Q1 Earnings & Sales, Cut Down FY18 View
by Zacks Equity Research
Clorox (CLX) reported first-quarter fiscal 2018 results, wherein adjusted earnings from continuing operations of $1.46 per share rose 7% year over year and also beat the Zacks Consensus Estimate.
Key Predictions for Earnings Reports of CLX, EL and KHC
by Zacks Equity Research
Clorox, Estee Lauder and Kraft Heinz are slated to report their quarterly earnings numbers on Nov 1.
Will Clorox's (CLX) 2020 Strategy Help Improve Q1 Earnings?
by Zacks Equity Research
Clorox (CLX) is riding on its 2020 Strategy, cost containment efforts and other growth initiatives. However, it remains vulnerable to the threats of rising commodity costs and stiff competition.
Why Is Clorox (CLX) Up 2.4% Since the Last Earnings Report?
by Zacks Equity Research
Clorox (CLX) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clorox (CLX) Q4 Earnings & Sales Beat the Zacks Consensus
by Zacks Equity Research
The Clorox Company (CLX) released 4Q17 results, wherein earnings benefited from strong sales and cost savings. Sales were backed by favorable volumes and pricing.
Clorox (CLX) Tops Q4 Earnings & Sales, Initiates FY18 View
by Zacks Equity Research
The Clorox Company (CLX) reported fourth-quarter fiscal 2017 results, wherein adjusted earnings from continuing operations of $1.53 per share rose 21% year over year and also beat the Zacks Consensus Estimate of $1.49.
Consumer Staples Stocks Earnings Roster for Aug 3: CLX, CHD
by Zacks Equity Research
Let's take a look at a couple of Consumer Staples stocks that are queued up for earnings releases on Aug 3.
Why Earnings Season Could Be Great for Clorox (CLX)
by Zacks Equity Research
Clorox (CLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Stericycle (SRCL) to Report Q2 Earnings: What Lies Ahead?
by Zacks Equity Research
Focus on increasing operational efficiency and continuous investments in data analytic capabilities to improve its performance are likely to drive Stericycle's (SRCL) Q2 earnings.
Will Declining Volumes Hurt Altria's (MO) Earnings in Q2?
by Zacks Equity Research
Despite strong brand portfolio, we believe declining demand for cigarettes due to the ongoing anti-tobacco campaigns and rising cigarette prices will continue to hurt Altria's (MO) earnings.
What's in Store for Philip Morris (PM) this Earnings Season?
by Zacks Equity Research
We expect Philip Morris' (PM) smoke-free efforts to help second-quarter earnings, offsetting the impact of cigarette volume declines.
Retail in Transformation Mode: Will Players Benefit?
by Zacks Equity Research
With respect to seasonal shopping periods, it is that time of the year when retailers are getting ready for a major spending event: Back-to-School.
4 Reasons to Retain Clorox (CLX) Stock in Your Portfolio
by Zacks Equity Research
Clorox Inc. (CLX) is doing well on the back of its solid surprise trend, robust outlook, impressive stock performance, progress on 2020 Strategy, diversified brand portfolio and disciplined capital strategy.